

MARYLOU SUDDERS Secretary

The Commonwealth of Massachusetts Executive Office of Health and Human Services One Ashburton Place, Room 1109 Boston, Massachusetts 02108

Tel: (617) 573-1600 Fax: (617) 573-1891 www.mass.gov/eohhs

Administrative Bulletin 20-88

101 CMR 320.00: Clinical Laboratory Services

Effective on dates found in table below.

Procedure Code Update

Pursuant to 101 CMR 320.01(3): *Coding Updates and Corrections*, the Executive Office of Health and Human Services (EOHHS) is adding new procedure codes for clinical laboratory services relating to testing for Coronavirus Disease 2019 (COVID-19). As set forth in 101 CMR 320.01(3)(c), rates for newly added codes are calculated according to the rate methodology used in setting clinical laboratory rates. Added codes without Medicare fees are reimbursed at individual consideration (I.C.). The rate listed in this administrative bulletin is applicable until revised rates are issued by the EOHHS.

The following table includes the added codes, rates, descriptions and effective dates:

Code	Rate	Description	Effective Dates of Service On or After
86408	I.C.	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen	08/10/2020
86409	I.C.	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer	08/10/2020



Code	Rate	Description	Effective Dates of Service On or After
86413	I.C.	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) antibody,quantitative	09/08/2020
87636	I.C.	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	10/07/2020
87637	I.C.	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	10/07/2020
87811	I.C.	Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	10/07/2020